Altimmune, Inc.
ALTHeld by 4 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying4 funds opened new positions. Next phase2 readout (Pemvidutide): May 2026. Short interest: 20.1% of float.
Held by 4 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying4 funds opened new positions. Next phase2 readout (Pemvidutide): May 2026. Short interest: 20.1% of float.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.